Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
  • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Definitions

• the present invention relates to novel polyisoprene compounds, salts thereof, process for the preparation thereof, and use thereof as a pharmaceutical composition to cure a digestive ulcer.
• Medicines for curing the digestive ulcer have been, in general, classified into two groups of an inhibitor to offensive factors and another group of intensificator to defensive factors.
• the former type drugs have been greatly developed, and for instance, a drug of "Cimetidine” which is one of exemplar compounds in the group and one of antagonists to histamine H2 receptor has provided such a great contribution of that it is excellent high curing ratio to the digestive ulcer, in comparison with other drugs to change a prior surgical treatment which has been mainly employed into an internal treatment administrating the drug.
• those drugs are inhibitors to offensive factors and its basis lies in inhibiting secretion of acid in the stomach. This means that if this type drug shows a strong inhibition, it also shows higher acid rebound, and therefor, it becomes such a serious problem that a relapse of the digestive ulcer may happen, when an administration of the drug was cheesed, in accordance with a diagnosis of that the disease has been cured.
• drugs of "Gefarnate”, “Cetraxate”, “Teprenone” and the like have been developed, as the intensificators to defensive factors and have widely been employed for clinical treatment of the digestive ulcer, since those show a little side-effect and may be administered currently with another drug.
• a main object of the invention is to provide a compound and a salt thereof which belong to the group of intensificator to defensive factors, show powerful anti-ulcer activity, and do not cause a relapse of the ulcer, after cured thereof.
• Additional, but important objects of the invention are provide a process for the preparation of the compound and salts thereof as well as a pharmaceutical composition which contains as an effective ingredient the compound or salt to cure the digestive ulcer.
• the inventors have checked as to the known drugs of "Gefarnate” and “Teprenone” belonging to the intensificators to defensive factors, based on their attention to a polyisoprene skeleton as a basic structure of the drugs, and then they energetically studied and investigated as to a modification of the structure.
• the problem in the prior arts can be dissolved and said main object can be attained by a polyisoprene compound of the formula wherein Y is S, O, NH or l is an integer of 2 - 10, Z is a group of R1 and R2 are same or different and each means a hydrogen atom or an alkyl group having C1 ⁇ 4, m is an integer of 0 or 1, and n is an integer of 0, 1 or 2, and a salt thereof.
• the alkyl group having C1 ⁇ 4 may be a straight-chain or branched-chain alkyl group.
• straight-chain alkyl radicals methyl, ethyl, n-propyl, n-butyl and the like may be listed.
• branched-chain alkyl radicals isopropyl, isobutyl, sec-butyl, tert-butyl and the like may be listed.
• the salts according to the invention are, of course, non-toxic salts which can be pharmacologically accepted.
• acids for forming the salts hydrochloric acid, sulfuric acid, hydrobromic acid and the like mineral acids; and methanesulfonic acid, fumaric acid, maleic acid and the like organic acids can be listed.
• the compounds of the formula wherein Y1 is sulfur atom; and R1, R2 and l have the meanings as referred to, and a salt thereof can be prepared by reacting in the presence of a base a compound of the formula wherein X is a halogen atom and l has the meaning as referred to, with a compound of the formula wherein Y1, R1 and R2 have the meanings as referred to, and if necessary, converting the resulting compound into the salt.
• the compound (IV) as raw material for said reaction can be prepared by halogenating a compound wherein l has the meaning as referred to, which has been marketed.
• the halogenation can be carried out by stirring one of the compounds (III) and a halogenation agent in an inert solvent at -20 to 100°C for 0.5 to 7 hours.
• a halogenation agent hydrogen halogenide, phosphorus halogenide (in the presence of pyridine or quinoline), triphenylphosphine-carbon tetrahalogenide, sulfonyl halogenide, sulfonium halogenide, and thionyl halogenide can be listed.
• N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, hexamethylphosphoric triamide or the like aprotic solvent, ethyl ether, dioxane, tetrahydrofuran or the like ether, benzene, toluene, xylene or the like aromatic hydrocarbon, carbon tetrachloride, n-hexane, petroleum ether or a mixture thereof can be employed.
• sodium carbonate, potassium carbonate or the like alkali carbonate, sodium bicarbonate or the like alkali hydrogen carbonate, triethylamine, N,N-dimethyl aniline, pyridine, 1,8-azabicyclo[5.4.0]undec-7-ene or the like organic amine, sodium hydride, sodium amide or the like can be employed.
• a condensation agent such as 18-crown-6 or the like crown ether may be added.
• the reaction between the compounds iV and V can be carried out by dissolving the compounds in an inert solvent and stirring the solution for 2 to 24 hours at 0 - 100°C , in the presence of said base.
• the solvent N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, hexamethylphosphoric triamide or the like aprotic solvent, dioxane, tetrahydrofuran or the like ether, benzene, toluene, xylene or the like aromatic hydrocarbon, or a mixture thereof can be employed.
• a molar ratio of compounds IV, V and the base of about 1.0 : 1.0 - 1.5 : 1.0 - 1.5 is preferable.
• the compounds of the formula wherein Y2 is hydrogen substituted nitrogen atom, R1, R2, l and m have the meanings as referred to, and a salt thereof can be prepared by reacting a compound of the formula wherein l and X have the meanings as referred to, with a compound of the formula wherein Y2, R1, R2 and m have the meanings as referred to, and if necessary converting the resulting compound into the salt.
• the reaction can be carried out by dissolving the compounds IV and VII into an inert solvent and stirring the solution for 2 - 24 hours at -20 - 100°C . It is preferable to set a mol ratio (VII/IV) between the compounds as about 1.0 - 1.5, and more preferably as 1.2.
• N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide,hexamethylphosphoric triamide or the like aprotic solvent, ethyl ether, dioxane, tetrahydrofuran, or the like ether, benzene, toluene, xylene or the like aromatic hydrocarbon, methanol, ethanol or the like alcohol or a mixture thereof can be employed. If necessary, a base may be added in the reaction system.
• sodium carbonate, potassium carbonate or the like alkali carbonate, sodium bicarbonate or the like alkali hydrogen carbnonate, triethylamine, N,N-dimethylaniline, pyridine, 1,8-azabicyclo[5.4.0]-undec-7-ene or the like organic amine, sodium hydride, sodium amide or the like can be employed.
• the compounds of the formula wherein Y1, R1, R2, l and n have the meanings as referred to, and a salt thereof can be prepared by reacting, in the presence of a base, a compound of the formula wherein Y1 and l have the meanings as referred to, with a compound of the formula wherein R1, R2, X and n have the meanings as referred to, and if necessary converting the resulting compound into the salt.
• the base for the reaction between the compounds IX and X sodium carbonate, potassium carbonate or the like alkali carbonate, sodium bicarbonate or the like alkali hydrogen carbonate; triethylamine, N,N-dimethylaniline, pyridine or the like organic amine can be employed.
• the reaction between the compounds IX and X can be carried out by dissolving the compounds in an inert solvent, and stirring the solution for 1 - 24 hours at -20 - 60°C , in the presence of the base.
• N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, hexamethylphosphric triamide or the like aprotic solvent, dioxane, tetrahydrofuran or the like ether, benzene, toluene, xylene or the like aromatic hydrocarbon, pyridine or a mixture thereof can be employed. It is preferable to react the compounds IX and X in the pyridine at 0 - 30°C .
• One of the raw materials, namely the compound X can easily be synthesized in accordance with the method as disclosed in Jap. Pat. No. Sho 62 - 56489(A).
• the compound of the formula wherein Y1, R1 and l have the meanings as referred to, and a salt thereof can be prepared by reacting a compound of the formula wherein Y1 and l have the meanings as referred to, with a compound of the formula reacting the resulting compound of the formula wherein Y1 and l have the meanings as referred to, with a compound of the formula H2NR1 (XIV) wherein R1 has the meaning as referred to, and if necessary, converting the resulting compound into the salt.
• One of the raw materials, namely the compound (XII) can easily be synthesized in accordance with known methods ["Chem. Ber.”, Vol. 52, page 542 (1919) and "Chem. Ber.”, Vol. 100. page 591 (1967)].
• reaction between the compounds XIII and XIV can be carried out by dissolving the compounds in an inert solvent or dissolving the compound XIII into the compound XIV, and stirring the solution for 0.1 - 5 hours at 0 - 100°C .
• N,N-dimethylformamide, N,N-Dimethylacetamide, dimethylsulfoxide, hexamethylphosphoric triamide or the like aprotic solvent, ethyl ether, dioxane, tetrahydrofuran or the like ether, benzene, toluene, xylene or the like aromatic hydrocarbon, methanol, ethanol or the like alcohol, acetonitrile, or a mixture thereof can be employed.
• a medicine shall be prepared by using as an effective ingredient the compound or salt thereof according to the invention, there is no limitation in its form and therefore, it may take in a solid form such as a tablet, pill, capsule, powder, granule, suppository and the like; or a liquid form such as a solution, suspension, emulsion and the like.
• the medicine can be prepared in a conventional manner.
• a starch, lactose, glucose, calcium phosphate, magnesium stearate, gum arabic or the like filler may be added. If necessary, conventional additives such as a lublicant, disintegrator, coating agent, coloring may also be used. While, for preparing the liquid type medicines, a stabilizer, solubilizing agent, suspending agent, emulsifier, buffer, preservative or the like may be employed.
• An amount of dosage of the compound or salt according to the invention depends on various factors such as kind of same to be selected, form of the medicine, condition of illness, age of the patient, but on case for an adult, an amount of about 0.1 - 2000mg/day and more particularly 10 - 150mg/day is suitable.
• triphenylphosphine 29.7g, 113mmol was added to a solution of 3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaen-1-ol (54.9g, 87.0mmol) in 78ml of carbon tetrachloride.
• Example 1-a The procedure described in Example 1-a) was repeated except that phytol (3,7,11,15-tetramethyl-2-hexadecaen-1-ol (25.8g, 87.2mmol) was employed as the starting material in place of 3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaen-1-ol, to afford 24.1g (88.0%) of the desired compound, as a brown oil.
• Example 1-a The procedure described in Example 1-a) was repeated except that gelaniol (3,7-dimethyl-2,6-octadien-1-ol, 13.4g, 87.0mmol) was employed as the starting material in place of 3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaen-1-ol, to afford 13.7g (91.3%) of the desired compound, as a brown oil.
• gelaniol (3,7-dimethyl-2,6-octadien-1-ol, 13.4g, 87.0mmol) was employed as the starting material in place of 3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaen-1-ol, to afford 13.7g (91.3%) of the desired compound, as a brown oil.
• Example 2-b The procedure described in Example 2-b) was repeated excepted that geranyl chloride [1-chloro-3,7-dimethyl-2,6-octadiene, 30.2g, 175mmol, prepared as described in Item a)] was employed as the starting material in place of phytyl chloride (1-chloro-3,7,11,15-tetramethyl-2-hexadecaene), to afford 30.6g (82.0%) of the desired compound, as a pale brown oil.
• Example 4-b The procedure described in Example 4-b) was repeated except that 1-bromo-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraene [9.3g, 26.3mmol, prepared as described in Item a)] was employed as the starting material in place of 1-bromo-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaene, to afford 6.5g (70.7%) of the desired compound, as a yellow oil.
• 1H-NMR spectrum (CDCl3) ⁇ ppm 1H-NMR spectrum (CDCl3) ⁇ ppm :
• Example 4-a The procedure in Example 4-a) was repeated except that 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol (12.7g, 57.3mmol) was employed as the starting material in place of 3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-ol, to afford 15.8g (96.9%) of the desired compound, as a yellow oil.
• Example 4-b The procedure in Example 4-b) was repeated except that 1-bromo-3,7,11-trimethyl-2,6,10-dodecatriene [7.5g, 26.3mmol, prepared by said Item b)] was employed as the starting material in place of 1-bromo-3,7,11,15,19,23,27,31,39-decamethyl-2,6,10,14,18, 22,26,30,34,38-tetracontadecaene, to afford 5.5g (74.3%) of the desired compound, as a pale yellow oil.
• 1H-NMR spectrum (CDCl3) ⁇ ppm 1H-NMR spectrum (CDCl3) ⁇ ppm :
• Example 10 The procedure described in Example 10 was repeated except that 2-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-ylthio)ethylamine (2.30g, 6.61mmol, prepared as described in Example 5) was employed as the starting material in place of 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30, 34, 38-tetracontadecaen-1-ylthio)ethylamine, to afford 2.67g (80.9%) of the desired compound, as a pale brown oil.
• Mass spectrum (EI/DI) m/z 500 (M+), 227, 196, 110 (base peak). 2910, 1670.
• 1H-NMR spectrum (CDCl3) ⁇ ppm 1H-NMR spectrum (CDCl3) ⁇ ppm :
• Results are shown in following Table 1 in terms of percent inhibition of anti-ulcer activity.
• ED50 represents the dose of test compound which gives 50% inhibition.
• An injection was prepared in a conventional manner with use of following ingredients and under sterile condition.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=14718198

Family Applications (2)

Family Applications After (1)

Country Status (3)

Families Citing this family (2)

Citations (9)

Family Cites Families (1)

• 1990
  • 1990-05-09 JP JP2117702A patent/JPH0418056A/ja active Pending
• 1991
  • 1991-05-03 EP EP19910107188 patent/EP0456124A3/en not_active Ceased
  • 1991-05-03 US US07/695,121 patent/US5177102A/en not_active Expired - Fee Related
  • 1991-05-03 EP EP95103608A patent/EP0663400A1/fr not_active Withdrawn

Patent Citations (9)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events